HOME >> BIOLOGY >> NEWS
University of Maryland research reveals true target of calcium channel blockers

Researchers at the University of Maryland School of Medicine have discovered that calcium channel blockers--widely used to treat heart problems and high blood pressure--work differently than previously thought. Their findings, published in the December issue of the American Journal of Physiology, may open the door to a different approach to treatment, with new, more effective medications that have a more precise therapeutic focus than current treatments.

The researchers found that calcium channel blockers primarily affect a group of cellular calcium channels in small arteries called "store-operated" channels. Prior to this discovery, scientists thought the blockers selectively affected what are known as "voltage-gated" channels.

"Our research has significant implications for the future treatment of heart disease and hypertension," says the study's senior author, Mordecai P. Blaustein, M.D., professor and chair of the Department of Physiology at the University of Maryland School of Medicine. "Armed with this knowledge, it should be possible to look for a new class of drugs that would cause fewer side effects."

"There are some observations that are a leap forward, not merely an incremental step," says C. William Balke, M.D., professor of medicine and physiology and head of the Division of Cardiology at the University of Maryland School of Medicine and the University of Maryland Medical Center. "This could easily be a leap. It certainly could change our paradigm for the treatment of hypertension," adds Dr. Balke.

Calcium, a mineral, is essential for the functioning of a number of systems in the body, including the pumping action of the heart and the contraction and relaxation of the smooth muscles that line blood vessel walls to regulate blood pressure. Too much tone or constriction can cause small arteries to narrow and increase their resistance to blood flow, leading to high blood pressure and forcing the heart to work harder.
'"/>

Contact: Larry Roberts
lroberts@som.umaryland.edu
410-706-7590
University of Maryland Medical Center
4-Dec-2002


Page: 1 2 3

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
Cached News: